Stockscreener 앱 받기
11.47
3.29%
-0.39
Arvinas Inc 주식(ARVN)의 최신 뉴스
Aug Closing: Is Arvinas Inc stock ready for breakoutEntry Point & Consistent Return Investment Signals - moha.gov.vn
(ARVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN
Arvinas announces preclinical data for ARV-393 - MSN
Can Arvinas Inc. stock sustain institutional interestMarket Movement Recap & Real-Time Chart Pattern Alerts - Улправда
Will Arvinas Inc. stock remain a Wall Street favoriteMarket Movers & Fast Gaining Stock Reports - DonanımHaber
Will Arvinas Inc. stock deliver better than expected guidanceEarnings Recap Report & Reliable Volume Spike Alerts - Улправда
Price Action: Why Arvinas Inc. stock remains on buy listsExit Point & Trade Opportunity Analysis - Улправда
(ARVN) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Possible Bearish Signals With Arvinas Insiders Disposing Stock - simplywall.st
Barclays maintains Arvinas (ARVN) overweight recommendation - MSN
Barclays Raises Price Target for Arvinas (ARVN) to $18 | ARVN St - GuruFocus
Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN - MarketBeat
Armistice Capital LLC Invests $4.12 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Velan Capital Investment Management LP Takes Position in Arvinas, Inc. $ARVN - MarketBeat
Diadema Partners LP Invests $710,000 in Arvinas, Inc. $ARVN - MarketBeat
Arvinas reveals promising preclinical data for ARV-393 - MSN
Arvinas Reveals Promising Preclinical Data for ARV-393 - TipRanks
Arvinas, Inc. Announces Preclinical Data for ARV-393 Combination - TradingView
22NW LP Acquires Shares of 413,533 Arvinas, Inc. $ARVN - MarketBeat
Arvinas (ARVN) Reveals Promising Preclinical Data for Cancer Tre - GuruFocus
Published on: 2025-12-06 23:24:37 - BỘ NỘI VỤ
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - The Manila Times
Arvinas, Inc. Announces Phase 1 Clinical Trial Initiation for ARV-393 Plus Glofitamab in Diffuse Large B-Cell Lymphoma Following Promising Preclinical Data - Quiver Quantitative
Why Arvinas Inc. stock could benefit from AI revolutionProfit Target & AI Forecasted Stock Moves - Newser
Franklin Resources Inc. Grows Stake in Arvinas, Inc. $ARVN - MarketBeat
Why Arvinas Inc. stock is considered a top pickBear Alert & Momentum Based Trading Signals - Newser
ARVN: Robust clinical pipeline advances and strong cash position support growth into 2028 - TradingView
Will Arvinas Inc. stock continue upward momentumIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Arvinas (ARVN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How the Narrative Around Arvinas Is Shifting Amid Strategic Moves and Analyst Uncertainty - Yahoo Finance
52,980 Shares in Arvinas, Inc. $ARVN Acquired by SG Americas Securities LLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN - The National Law Review
New Highs: Why Arvinas Inc. stock remains on buy listsJuly 2025 Update & Accurate Intraday Trade Tips - moha.gov.vn
Entropy Technologies LP Purchases Shares of 32,491 Arvinas, Inc. $ARVN - MarketBeat
Arvinas Inc Stock Analysis and ForecastLow Beta Stocks & Outstanding Investment Returns - earlytimes.in
Published on: 2025-11-27 09:33:44 - BỘ NỘI VỤ
Arvinas (Nasdaq: ARVN) plans fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Arvinas to present vepdegestrant breast cancer data at SABCS By Investing.com - Investing.com Nigeria
Arvinas to present vepdegestrant breast cancer data at SABCS - Investing.com
Arvinas, Inc. Announces Multiple Abstract Presentations on Vepdegestrant at San Antonio Breast Cancer Symposium 2025 - Quiver Quantitative
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development ... - Enidnews.com
Arvinas Announces Data Presentations from the Vepdegestrant - GlobeNewswire
Arvinas: Approvable, But Asset Looks Mediocre, Initiating With A Hold Rating (NASDAQ:ARVN) - Seeking Alpha
Arvinas (NASDAQ: ARVN) showcases vepdegestrant breast cancer data at 2025 SABCS - Stock Titan
Promising Biotech Stocks To ConsiderNovember 18th - MarketBeat
Can Arvinas Inc. stock beat market expectations this quarterTrend Reversal & Fast Exit/Entry Strategy Plans - newser.com
Arvinas (NASDAQ:ARVN) Stock Price Down 7%Should You Sell? - MarketBeat
0.57%
자본화:
|
볼륨(24시간):